Velarion · Company Intelligence
Compensation Brief
Fiscal year 2024 · Filings through 2026-04-29

Blueprint Medicines (BPMC)

CEO Kathryn Haviland was paid $13,477,004 in fiscal year 2024, ↑ up 109.5% from fiscal year 2023, the 76th percentile of its disclosed peer group (SEC filing 0001558370-25-005415 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$13,477,004 ↑
Kathryn Haviland total, FY2024
76th
CEO pay percentile vs peers
35:1
CEO-to-median pay ratio
95.93%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Kathryn Haviland (President and Chief Executive Officer), FY2024 total compensation $13,477,004 (base salary $821,363) [exec_comp, SEC accession 0001558370-25-005415, filed 2025-04-24]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

01

Summary Compensation Table — fiscal year 2024

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Kathryn Haviland$821,363$0$7,472,480$4,315,144$854,217$0$13,800$13,477,004
President and Chief Executive Officer
Christina Rossi668,41003,700,2181,618,179541,412013,8006,542,019
Chief Operating Officer
Fouad Namouni671,80902,649,3601,618,179544,165013,8005,497,313
President, Research and Development
Percy Carter619,23302,687,0501,348,483417,982059,7155,132,463
Chief Scientific Officer
Michael Landsittel573,59301,868,2001,348,483387,175013,8004,191,251
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY2023→2024
Kathryn Haviland$13,477,004$6,432,012$6,217,694↑ +7,044,992
Christina Rossi6,542,0192,806,2092,769,000↑ +3,735,810
Fouad Namouni5,497,3132,801,7782,810,182↑ +2,695,535
Percy Carter5,132,4632,299,8271,992,743↑ +2,832,636
Michael Landsittel4,191,2512,194,8302,363,511↑ +1,996,421

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Blueprint Medicines's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper BPMC reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against BPMC
33 companies name BPMC as a compensation peer

The list of companies that name BPMC as a peer is temporarily unavailable — recheck shortly.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2024 total
Percy CarterChief Scientific Officer$5,132,463
Fouad NamouniPresident$5,497,313
Christina RossiCOO$6,542,019
Kathryn HavilandCEO$13,477,004
Michael LandsittelCFO$4,191,251
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2024 total
Alexis BorisyIndependent Director$549,690
Daniella BeckmanIndependent Director$574,690
Habib DableIndependent Director$564,990
Jeffrey W. AlbersChair of the Board$586,190
John TsaiIndependent Director$549,690
Lonnel CoatsIndependent Director$572,590
Lynn SeelyLead Independent Director$606,190
Mark GoldbergIndependent Director$586,690
Nicholas LydonIndependent Director$569,690
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Christina RossiCHIEF OPERATING OFFICER2025-05-05D607$101$61,289CommonForm 4 ↗
Ariel HurleyPRINCIPAL ACCOUNTING OFFICER2025-05-05A2,75254148,966CommonForm 4 ↗
Ariel HurleyPRINCIPAL ACCOUNTING OFFICER2025-05-05D2,75200Derivative, Class A CommonForm 4 ↗
Ariel HurleyPRINCIPAL ACCOUNTING OFFICER2025-05-05D10010510,478CommonForm 4 ↗
Ariel HurleyPRINCIPAL ACCOUNTING OFFICER2025-05-05D1,252103128,343CommonForm 4 ↗
Christina RossiCHIEF OPERATING OFFICER2025-05-05D18010318,508CommonForm 4 ↗
Christina RossiCHIEF OPERATING OFFICER2025-05-05D14410414,913CommonForm 4 ↗
Christina RossiCHIEF OPERATING OFFICER2025-05-05D1,343102136,677CommonForm 4 ↗
Christina RossiCHIEF OPERATING OFFICER2025-05-19D80410080,513CommonForm 4 ↗
Christina RossiCHIEF OPERATING OFFICER2025-05-19D571025,798CommonForm 4 ↗
Christina RossiCHIEF OPERATING OFFICER2025-05-19D1,413101142,247CommonForm 4 ↗
Jeffrey W. AlbersDirector2025-05-27D4,350101439,437CommonForm 4 ↗
Jeffrey W. AlbersDirector2025-05-27D65010266,255CommonForm 4 ↗
Jeffrey W. AlbersDirector2025-05-27D5,00000Derivative, Class A CommonForm 4 ↗
Jeffrey W. AlbersDirector2025-05-27A5,00036180,250CommonForm 4 ↗
Percy CarterCHIEF SCIENTIFIC OFFICER2025-06-03D2,418128309,214CommonForm 4 ↗
Percy CarterCHIEF SCIENTIFIC OFFICER2025-06-03D24112830,819CommonForm 4 ↗
Alexis BorisyDirector2025-06-18A3,902128499,924CommonForm 4 ↗
Mark GoldbergDirector2025-06-18A3,902128499,924CommonForm 4 ↗
Lonnel CoatsDirector2025-06-18A3,90212,81249,992,424CommonForm 4 ↗
John TsaiDirector2025-06-18A3,902128499,924CommonForm 4 ↗
Daniella BeckmanDirector2025-06-18A3,902128499,924CommonForm 4 ↗
Habib DableDirector2025-06-18A3,902128499,924CommonForm 4 ↗
Jeffrey W. AlbersDirector2025-06-18A3,902128499,924CommonForm 4 ↗
Lynn SeelyDirector2025-06-18A3,902128499,924CommonForm 4 ↗
Christina RossiCHIEF OPERATING OFFICER2025-07-03D1,172128150,309CommonForm 4 ↗
Percy CarterCHIEF SCIENTIFIC OFFICER2025-07-03D1,051128134,791CommonForm 4 ↗
Michael LandsittelChief Financial Officer2025-07-17D43,175——CommonForm 4 ↗
Michael LandsittelChief Financial Officer2025-07-17A21,353——CommonForm 4 ↗
Fouad NamouniPRESIDENT, R & D2025-07-17D65,000——Derivative, Class A CommonForm 4 ↗
Mark GoldbergDirector2025-07-17D5,300——Derivative, Class A CommonForm 4 ↗
Mark GoldbergDirector2025-07-17D7,500——Derivative, Class A CommonForm 4 ↗
Mark GoldbergDirector2025-07-17D10,909——Derivative, Class A CommonForm 4 ↗
Mark GoldbergDirector2025-07-17D18,254——CommonForm 4 ↗
Mark GoldbergDirector2025-07-17D3,902——CommonForm 4 ↗
Alexis BorisyDirector2025-07-17D5,300——Derivative, Class A CommonForm 4 ↗
Christina RossiChief Operating Officer2025-07-17D26,400——Derivative, Class A CommonForm 4 ↗
Christina RossiChief Operating Officer2025-07-17D30,000——Derivative, Class A CommonForm 4 ↗
Lynn SeelyDirector2025-07-17D4,570——Derivative, Class A CommonForm 4 ↗
Lynn SeelyDirector2025-07-17D5,300——Derivative, Class A CommonForm 4 ↗
Lynn SeelyDirector2025-07-17D10,909——Derivative, Class A CommonForm 4 ↗
Lynn SeelyDirector2025-07-17D10,909——Derivative, Class A CommonForm 4 ↗
Lynn SeelyDirector2025-07-17D21,818——Derivative, Class A CommonForm 4 ↗
Tracey L. McCainEVP & Chief Legal Officer2025-07-17D5,000——Derivative, Class A CommonForm 4 ↗
Jeffrey W. AlbersDirector2025-07-17D5,300——Derivative, Class A CommonForm 4 ↗
Jeffrey W. AlbersDirector2025-07-17D15,000——Derivative, Class A CommonForm 4 ↗
Debra Durso-BumpusChief People Officer2025-07-17D22,000——Derivative, Class A CommonForm 4 ↗
Jeffrey W. AlbersDirector2025-07-17D80,000——Derivative, Class A CommonForm 4 ↗
Jeffrey W. AlbersDirector2025-07-17D144,755——CommonForm 4 ↗
Daniella BeckmanDirector2025-07-17D7,000——Derivative, Class A CommonForm 4 ↗
Debra Durso-BumpusChief People Officer2025-07-17A21,353——CommonForm 4 ↗
Daniella BeckmanDirector2025-07-17D10,842——CommonForm 4 ↗
Kathryn HavilandDirector2025-07-17D39,000——Derivative, Class A CommonForm 4 ↗
Mark GoldbergDirector2025-07-17D4,570——Derivative, Class A CommonForm 4 ↗
Kathryn HavilandDirector2025-07-17D591——Derivative, Class A CommonForm 4 ↗
Christina RossiChief Operating Officer2025-07-17D20,628——CommonForm 4 ↗
Percy CarterChief Scientific Officer2025-07-17D25,000——Derivative, Class A CommonForm 4 ↗
Lynn SeelyDirector2025-07-17D4,500——Derivative, Class A CommonForm 4 ↗
L. Becker HewesChief Medical Officer2025-07-17D13,490——Derivative, Class A CommonForm 4 ↗
Lonnel CoatsDirector2025-07-17D4,875——Derivative, Class A CommonForm 4 ↗
Ariel HurleyPrincipal Accounting Officer2025-07-17D9,494——Derivative, Class A CommonForm 4 ↗
Habib DableDirector2025-07-17D8,742——CommonForm 4 ↗
Michael LandsittelChief Financial Officer2025-07-17D26,125——Derivative, Class A CommonForm 4 ↗
Michael LandsittelChief Financial Officer2025-07-17D25,000——Derivative, Class A CommonForm 4 ↗
Kathryn HavilandDirector2025-07-17D80,000——Derivative, Class A CommonForm 4 ↗
Kathryn HavilandDirector2025-07-17D2——Derivative, Class A CommonForm 4 ↗
Kathryn HavilandDirector2025-07-17D70,729——CommonForm 4 ↗
Kathryn HavilandDirector2025-07-17D224,410——CommonForm 4 ↗
Percy CarterChief Scientific Officer2025-07-17D39,200——Derivative, Class A CommonForm 4 ↗
Percy CarterChief Scientific Officer2025-07-17D17,894——CommonForm 4 ↗
Lynn SeelyDirector2025-07-17D7,500——Derivative, Class A CommonForm 4 ↗
L. Becker HewesChief Medical Officer2025-07-17D19,271——Derivative, Class A CommonForm 4 ↗
L. Becker HewesChief Medical Officer2025-07-17D1,607——CommonForm 4 ↗
L. Becker HewesChief Medical Officer2025-07-17A21,353——CommonForm 4 ↗
Lonnel CoatsDirector2025-07-17D3,188——Derivative, Class A CommonForm 4 ↗
Lonnel CoatsDirector2025-07-17D11,818——Derivative, Class A CommonForm 4 ↗
Ariel HurleyPrincipal Accounting Officer2025-07-17D7,007——Derivative, Class A CommonForm 4 ↗
Ariel HurleyPrincipal Accounting Officer2025-07-17D6,375——Derivative, Class A CommonForm 4 ↗
Ariel HurleyPrincipal Accounting Officer2025-07-17D2,751——Derivative, Class A CommonForm 4 ↗
Ariel HurleyPrincipal Accounting Officer2025-07-17D12,000——Derivative, Class A CommonForm 4 ↗
Ariel HurleyPrincipal Accounting Officer2025-07-17D2,250——Derivative, Class A CommonForm 4 ↗
Ariel HurleyPrincipal Accounting Officer2025-07-17D3,378——CommonForm 4 ↗
Habib DableDirector2025-07-17D3,902——CommonForm 4 ↗
Michael LandsittelChief Financial Officer2025-07-17D10,000——Derivative, Class A CommonForm 4 ↗
Michael LandsittelChief Financial Officer2025-07-17D51,102——CommonForm 4 ↗
Ariel HurleyPrincipal Accounting Officer2025-07-17D10,000——Derivative, Class A CommonForm 4 ↗
Philina LeeChief Commercial Officer2025-07-17D20,669——Derivative, Class A CommonForm 4 ↗
Debra Durso-BumpusChief People Officer2025-07-17D25,000——Derivative, Class A CommonForm 4 ↗
Debra Durso-BumpusChief People Officer2025-07-17D21,125——Derivative, Class A CommonForm 4 ↗
Debra Durso-BumpusChief People Officer2025-07-17D15,367——Derivative, Class A CommonForm 4 ↗
Debra Durso-BumpusChief People Officer2025-07-17D51,103——CommonForm 4 ↗
Tracey L. McCainEVP & Chief Legal Officer2025-07-17D25,000——Derivative, Class A CommonForm 4 ↗
Tracey L. McCainEVP & Chief Legal Officer2025-07-17D25,000——Derivative, Class A CommonForm 4 ↗
Tracey L. McCainEVP & Chief Legal Officer2025-07-17D26,125——Derivative, Class A CommonForm 4 ↗
Tracey L. McCainEVP & Chief Legal Officer2025-07-17D28,500——Derivative, Class A CommonForm 4 ↗
Tracey L. McCainEVP & Chief Legal Officer2025-07-17D39,000——Derivative, Class A CommonForm 4 ↗
Tracey L. McCainEVP & Chief Legal Officer2025-07-17D51,103——CommonForm 4 ↗
Daniella BeckmanDirector2025-07-17D4,570——Derivative, Class A CommonForm 4 ↗
Mark GoldbergDirector2025-07-17D5,300——Derivative, Class A CommonForm 4 ↗
L. Becker HewesChief Medical Officer2025-07-17D9,115——Derivative, Class A CommonForm 4 ↗
Michael LandsittelChief Financial Officer2025-07-17D26,000——Derivative, Class A CommonForm 4 ↗
L. Becker HewesChief Medical Officer2025-07-17D50,165——CommonForm 4 ↗
Ariel HurleyPrincipal Accounting Officer2025-07-17D5,750——Derivative, Class A CommonForm 4 ↗
Ariel HurleyPrincipal Accounting Officer2025-07-17D11,399——Derivative, Class A CommonForm 4 ↗
Ariel HurleyPrincipal Accounting Officer2025-07-17D16,146——CommonForm 4 ↗
Habib DableDirector2025-07-17D4,570——Derivative, Class A CommonForm 4 ↗
Habib DableDirector2025-07-17D5,300——Derivative, Class A CommonForm 4 ↗
Michael LandsittelChief Financial Officer2025-07-17D22,000——Derivative, Class A CommonForm 4 ↗
Fouad NamouniPRESIDENT, R & D2025-07-17D31,956——CommonForm 4 ↗
Fouad NamouniPRESIDENT, R & D2025-07-17D83,281——CommonForm 4 ↗
Mark GoldbergDirector2025-07-17D4,500——Derivative, Class A CommonForm 4 ↗
Mark GoldbergDirector2025-07-17D4,500——Derivative, Class A CommonForm 4 ↗
Mark GoldbergDirector2025-07-17D4,875——Derivative, Class A CommonForm 4 ↗
Alexis BorisyDirector2025-07-17D4,570——Derivative, Class A CommonForm 4 ↗
Alexis BorisyDirector2025-07-17D5,300——Derivative, Class A CommonForm 4 ↗
Alexis BorisyDirector2025-07-17D4,500——Derivative, Class A CommonForm 4 ↗
Alexis BorisyDirector2025-07-17D4,500——Derivative, Class A CommonForm 4 ↗
Alexis BorisyDirector2025-07-17D7,500——Derivative, Class A CommonForm 4 ↗
Alexis BorisyDirector2025-07-17D74,160——CommonForm 4 ↗
Kathryn HavilandDirector2025-07-17D70,400——Derivative, Class A CommonForm 4 ↗
Kathryn HavilandDirector2025-07-17D80,000——Derivative, Class A CommonForm 4 ↗
Kathryn HavilandDirector2025-07-17D80,000——Derivative, Class A CommonForm 4 ↗
Kathryn HavilandDirector2025-07-17D26,125——Derivative, Class A CommonForm 4 ↗
Kathryn HavilandDirector2025-07-17D28,500——Derivative, Class A CommonForm 4 ↗
Kathryn HavilandDirector2025-07-17D32,500——Derivative, Class A CommonForm 4 ↗
Christina RossiChief Operating Officer2025-07-17D30,000——Derivative, Class A CommonForm 4 ↗
Christina RossiChief Operating Officer2025-07-17D80,000——Derivative, Class A CommonForm 4 ↗
Christina RossiChief Operating Officer2025-07-17D82,374——CommonForm 4 ↗
Percy CarterChief Scientific Officer2025-07-17D22,000——Derivative, Class A CommonForm 4 ↗
Percy CarterChief Scientific Officer2025-07-17D17,500——Derivative, Class A CommonForm 4 ↗
Percy CarterChief Scientific Officer2025-07-17D56,614——CommonForm 4 ↗
Lynn SeelyDirector2025-07-17D5,300——Derivative, Class A CommonForm 4 ↗
Lynn SeelyDirector2025-07-17D4,500——Derivative, Class A CommonForm 4 ↗
Lynn SeelyDirector2025-07-17D13,254——CommonForm 4 ↗
Lynn SeelyDirector2025-07-17D3,902——CommonForm 4 ↗
L. Becker HewesChief Medical Officer2025-07-17D22,000——Derivative, Class A CommonForm 4 ↗
L. Becker HewesChief Medical Officer2025-07-17D25,000——Derivative, Class A CommonForm 4 ↗
L. Becker HewesChief Medical Officer2025-07-17D26,125——Derivative, Class A CommonForm 4 ↗
Lonnel CoatsDirector2025-07-17D5,300——Derivative, Class A CommonForm 4 ↗
Jeffrey W. AlbersDirector2025-07-17D110,500——Derivative, Class A CommonForm 4 ↗
Jeffrey W. AlbersDirector2025-07-17D170,000——Derivative, Class A CommonForm 4 ↗
Jeffrey W. AlbersDirector2025-07-17D92,500——Derivative, Class A CommonForm 4 ↗
Philina LeeChief Commercial Officer2025-07-17D25,000——Derivative, Class A CommonForm 4 ↗
Philina LeeChief Commercial Officer2025-07-17D6,928——Derivative, Class A CommonForm 4 ↗
Philina LeeChief Commercial Officer2025-07-17D13,184——CommonForm 4 ↗
Philina LeeChief Commercial Officer2025-07-17D50,165——CommonForm 4 ↗
Debra Durso-BumpusChief People Officer2025-07-17D25,000——Derivative, Class A CommonForm 4 ↗
Debra Durso-BumpusChief People Officer2025-07-17D25,000——Derivative, Class A CommonForm 4 ↗
Debra Durso-BumpusChief People Officer2025-07-17D26,125——Derivative, Class A CommonForm 4 ↗
Debra Durso-BumpusChief People Officer2025-07-17D30,500——Derivative, Class A CommonForm 4 ↗
Debra Durso-BumpusChief People Officer2025-07-17D19,856——CommonForm 4 ↗
Tracey L. McCainEVP & Chief Legal Officer2025-07-17D22,000——Derivative, Class A CommonForm 4 ↗
Tracey L. McCainEVP & Chief Legal Officer2025-07-17D25,000——Derivative, Class A CommonForm 4 ↗
Tracey L. McCainEVP & Chief Legal Officer2025-07-17D29,900——Derivative, Class A CommonForm 4 ↗
Tracey L. McCainEVP & Chief Legal Officer2025-07-17D55,000——Derivative, Class A CommonForm 4 ↗
Tracey L. McCainEVP & Chief Legal Officer2025-07-17D37,092——CommonForm 4 ↗
Fouad NamouniPRESIDENT, R & D2025-07-17D30,000——Derivative, Class A CommonForm 4 ↗
Christina RossiChief Operating Officer2025-07-17D30,000——Derivative, Class A CommonForm 4 ↗
Christina RossiChief Operating Officer2025-07-17D26,125——Derivative, Class A CommonForm 4 ↗
Christina RossiChief Operating Officer2025-07-17D28,500——Derivative, Class A CommonForm 4 ↗
Christina RossiChief Operating Officer2025-07-17D6,500——Derivative, Class A CommonForm 4 ↗
Lonnel CoatsDirector2025-07-17D4,570——Derivative, Class A CommonForm 4 ↗
Lonnel CoatsDirector2025-07-17D5,300——Derivative, Class A CommonForm 4 ↗
Lonnel CoatsDirector2025-07-17D10,909——Derivative, Class A CommonForm 4 ↗
Lonnel CoatsDirector2025-07-17D10,909——Derivative, Class A CommonForm 4 ↗
Lonnel CoatsDirector2025-07-17D6,144——CommonForm 4 ↗
Percy CarterChief Scientific Officer2025-07-17D25,000——Derivative, Class A CommonForm 4 ↗
Percy CarterChief Scientific Officer2025-07-17A21,353——CommonForm 4 ↗
John TsaiDirector2025-07-17D4,570——Derivative, Class A CommonForm 4 ↗
John TsaiDirector2025-07-17D5,300——Derivative, Class A CommonForm 4 ↗
John TsaiDirector2025-07-17D7,950——Derivative, Class A CommonForm 4 ↗
John TsaiDirector2025-07-17D8,742——CommonForm 4 ↗
Daniella BeckmanDirector2025-07-17D5,300——Derivative, Class A CommonForm 4 ↗
Daniella BeckmanDirector2025-07-17D5,300——Derivative, Class A CommonForm 4 ↗
Daniella BeckmanDirector2025-07-17D3,902——CommonForm 4 ↗
Habib DableDirector2025-07-17D7,950——Derivative, Class A CommonForm 4 ↗
Fouad NamouniPRESIDENT, R & D2025-07-17D30,000——Derivative, Class A CommonForm 4 ↗
Fouad NamouniPRESIDENT, R & D2025-07-17D30,000——Derivative, Class A CommonForm 4 ↗
Fouad NamouniPRESIDENT, R & D2025-07-17A39,456——CommonForm 4 ↗
Fouad NamouniPRESIDENT, R & D2025-07-17D26,125——Derivative, Class A CommonForm 4 ↗
Fouad NamouniPRESIDENT, R & D2025-07-17D26,400——Derivative, Class A CommonForm 4 ↗
Alexis BorisyDirector2025-07-17D4,875——Derivative, Class A CommonForm 4 ↗
Alexis BorisyDirector2025-07-17D3,902——CommonForm 4 ↗
Michael LandsittelChief Financial Officer2025-07-17D25,000——Derivative, Class A CommonForm 4 ↗
Michael LandsittelChief Financial Officer2025-07-17D25,000——Derivative, Class A CommonForm 4 ↗
Michael LandsittelChief Financial Officer2025-07-17D25,000——Derivative, Class A CommonForm 4 ↗
Jeffrey W. AlbersDirector2025-07-17D4,570——Derivative, Class A CommonForm 4 ↗
Jeffrey W. AlbersDirector2025-07-17D90,000——Derivative, Class A CommonForm 4 ↗
Jeffrey W. AlbersDirector2025-07-17D5,777——CommonForm 4 ↗
John TsaiDirector2025-07-17D3,902——CommonForm 4 ↗
Michael LandsittelChief Financial Officer2025-07-17D19,500——Derivative, Class A CommonForm 4 ↗
Lonnel CoatsDirector2025-07-17D4,500——Derivative, Class A CommonForm 4 ↗
Lynn SeelyDirector2025-07-17D4,875——Derivative, Class A CommonForm 4 ↗
Philina LeeChief Commercial Officer2025-07-17D22,000——Derivative, Class A CommonForm 4 ↗
Philina LeeChief Commercial Officer2025-07-17D8,650——Derivative, Class A CommonForm 4 ↗
Ariel HurleyPrincipal Accounting Officer2025-07-17A2,460——CommonForm 4 ↗
Philina LeeChief Commercial Officer2025-07-17A21,353——CommonForm 4 ↗
Kathryn HavilandDirector2025-07-17A129,210——CommonForm 4 ↗
Christina RossiChief Operating Officer2025-07-17A39,456——CommonForm 4 ↗
Tracey L. McCainEVP & Chief Legal Officer2025-07-17A21,353——CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2024

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Michael LandsittelRSU2024-03-01——12,500—$1,189,000
Kathryn HavilandPSU2024-03-0113,50027,000—54,0003,667,680
Michael LandsittelPSU2024-03-012,5005,000—10,000679,200
Fouad NamouniPSU2024-03-014,5009,000—18,0001,222,560
Percy CarterPSU2024-03-012,5005,000—10,000679,200
Christina RossiRSU2024-07-01——9,625—1,050,858
Christina RossiPSU2024-03-014,5009,000—18,0001,222,560
Fouad NamouniOPTION2024-03-01——30,000—1,618,179
Percy CarterOPTION2024-03-01——25,000—1,348,483
Percy CarterRSU2024-07-01——7,500—818,850
Kathryn HavilandRSU2024-03-01——40,000—3,804,800
Christina RossiRSU2024-03-01——15,000—1,426,800
Kathryn HavilandOPTION2024-03-01——80,000—4,315,144
Percy CarterRSU2024-03-01——12,500—1,189,000
Michael LandsittelOPTION2024-03-01——25,000—1,348,483
Fouad NamouniRSU2024-03-01——15,000—1,426,800
Christina RossiOPTION2024-03-01——30,000—1,618,179
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Michael Landsittel$1,189,000$679,200$1,348,48321.1%
Kathryn Haviland3,804,8003,667,6804,315,14431.1%
Fouad Namouni1,426,8001,222,5601,618,17928.6%
Percy Carter2,007,850679,2001,348,48316.8%
Christina Rossi2,477,6581,222,5601,618,17923.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Kathryn HavilandPSU27,000—$2,673,092
Percy CarterPSU5,000—495,017
Kathryn HavilandPSU20,700—3,206,667
Kathryn HavilandRSU20,000—1,744,400
Christina RossiOption1,633100.13—
Kathryn HavilandRSU40,000—3,488,800
Kathryn HavilandRSU30,000—2,616,600
Christina RossiRSU15,000—1,308,300
Fouad NamouniRSU15,000—1,308,300
Michael LandsittelRSU12,500—1,090,250
Percy CarterRSU12,500—1,090,250
Christina RossiRSU11,250—981,225
Fouad NamouniRSU11,250—981,225
Christina RossiPSU9,000—891,031
Fouad NamouniPSU9,000—891,031
Christina RossiRSU9,625—839,493
Christina RossiPSU5,400—836,522
Michael LandsittelOption7,81361.31—
Christina RossiOption16,87543.15—
Fouad NamouniPSU5,400—836,522
Percy CarterRSU4,374—381,500
Michael LandsittelRSU9,375—817,688
Percy CarterRSU9,375—817,688
Kathryn HavilandOption1,633100.13—
Christina RossiRSU7,500—654,150
Christina RossiOption24,37595.12—
Fouad NamouniRSU7,500—654,150
Percy CarterRSU7,500—645,150
Michael LandsittelRSU6,250—545,125
Michael LandsittelPSU5,000—495,017
Christina RossiRSU3,265—284,773
Percy CarterRSU5,460—476,221
Michael LandsittelPSU2,700—418,261
Percy CarterPSU2,700—418,261
Kathryn HavilandRSU3,265—284,773
Kathryn HavilandOption65,00095.12—
Percy CarterOption14,06343.15—
Michael LandsittelRSU3,265—284,773
Fouad NamouniRSU3,265—284,773
Michael LandsittelOption20,31395.12—
Kathryn HavilandOption25,00061.31—
Kathryn HavilandOption45,00043.15—
Michael LandsittelOption1,633100.13—
Michael LandsittelOption14,06343.15—
Christina RossiOption9,37561.31—
Fouad NamouniOption1,633100.13—
Fouad NamouniOption9,37561.31—
Fouad NamouniOption16,87543.15—
Fouad NamouniOption24,37595.12—
Percy CarterOption4,90089.16—
Percy CarterOption5,46961.31—
Percy CarterOption20,31395.12—
05

Incentive-plan design — the Compensation Discussion & Analysis

The compensation program is designed to promote company performance and reward value creation for stockholders by attracting, engaging, and retaining highly skilled executive talent. It aligns executives' interests with stockholders through long-term incentives linked to stock price performance and provides incentives that motivate the achievement of performance goals directly tied to business objectives and stockholder value.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantAon
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-06-1857,714,0692,450,82525,74495.93%Passed
20242024-04-2556,844,8791,345,31384,03797.69%Passed
20232023-06-2154,299,7041,010,25543,91498.17%Passed
20222022-06-2153,277,135916,09126,15298.31%Passed
20212021-06-0251,256,8301,208,06510,83997.7%Passed
20202020-06-2346,685,705963,65016,05597.98%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20252025-06-1895.93%a
20242024-04-2597.69%b
20232023-06-2198.17%c

a. Voting standard not stated in the filing.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of this proposal.”.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)35 : 1
CEO total compensation$13,477,004
Median employee compensation$389,871
08

Director compensation — fiscal year 2024

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Lynn SeelyIndependent · Lead Independent Director · Compensation (Chair) · Nominating/Governance$106,500$237,966$261,724——$606,190
Mark GoldbergIndependent · Audit · Compensation72,000237,966261,724—15,000586,690
Jeffrey W. AlbersNot independent · Board Chair86,500237,966261,724——586,190
Daniella BeckmanIndependent · Audit (Chair)75,000237,966261,724——574,690
Lonnel CoatsIndependent · Audit · Nominating/Governance (Chair)72,900237,966261,724——572,590
Nicholas LydonIndependent · Not standing for re-election50,000237,966261,724—20,000569,690
Habib DableIndependent · Compensation · Nominating/Governance65,300237,966261,724——564,990
John TsaiIndependent50,000237,966261,724——549,690
Alexis BorisyIndependent50,000237,966261,724——549,690
Kathryn HavilandEmployee director · Partial-year service—————0
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)25,000 / 20,000 / 13,000
Stock ownership guidelineAll of our directors are in compliance with our current stock ownership guidelines. See “Other Compensation Policies and Practices – Stock Ownership Guidelines” for more information.
09b

Total cost of the board

ComponentFY2024
Cash retainers and fees$628,200
Equity awards (grant-date value)$2,141,694
All other compensation$35,000
Total cost of the board$2,804,894

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2024

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Blueprint Medicines names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Blueprint Medicines.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Exelixis, Inc.2025Michael Morrissey$1,306,040$30,539,552$0$1,382,591$33,239,183
2PTC Therapeutic2025Matthew Klein958,50016,593,8004,399,7601,294,00023,266,326
3Halozyme Therapeutics, Inc.2025Helen Torley1,000,00019,350,1451,650,0141,147,50023,166,223
4United Therapeutics, Inc.2025Martine Rothblatt1,545,0056,067,9906,075,8044,281,87518,038,972
5Blueprint Medicines2024Kathryn Haviland821,3637,472,4804,315,144854,21713,477,004
6Neurocrine Biosciences, Inc.2025Kyle Gano920,0005,750,0235,750,006013,448,935
7Ionis Pharmaceuticals, Inc.2025Brett Monia1,051,7768,444,8381,438,105013,350,777
8BioCryst Pharmaceuticals, Inc.2025Jon Stonehouse728,466011,132,4581,052,63312,951,082
9Mirati Therapeutics, Inc.2022David Meek749,4236,043,8854,233,427438,98511,937,371
10Ultragenyx Pharmaceutical Inc.2025Emil Kakkis861,1008,364,9381,847,356299,66311,405,535
11Apellis Pharmaceuticals, Inc.2024Cedric Francois793,1934,779,8324,787,768010,957,451
12Amicus Therapeutics, Inc.2024Bradley Campbell767,3084,990,3652,105,62708,526,943
13ACADIA Pharmaceuticals Inc.2025Catherine Owen Adams930,0003,240,5583,234,797818,5598,256,518
14Alkermes, Inc.2025Richard Pops1,250,76905,020,8121,626,0007,915,081
15Sarepta Therapeutics, Inc.2025Douglas Ingram1,171,4256,000,0050649,0007,840,666
16CRISPR Therapeutics AG2025Samarth Kulkarni768,6223,474,9002,768,862659,0937,678,477
17Deciphera Pharmaceuticals, Inc.2023Steven Hoerter738,2001,935,0002,837,100487,2126,010,712
18Agios Pharmaceuticals, Inc.2025Brian Goff846,8641,291,6802,627,252592,8045,370,389

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Blueprint Medicines130%RSU 37 · Options 32 · PSU 31Yes — Relative Total Stockholder Return (rTSR)Aon
ACADIA Pharmaceuticals Inc.110%Options 50 · PSU 25 · RSU 25YesFrederic W. Cook & Co., Inc. (FW Cook)
Agios Pharmaceuticals, Inc.100%Option 40 · PSU 40 · RSU 20NoAon
Alkermes, Inc.130%PRSU 53 · RSU 24 · Option 23Yes — Relative Total Shareholder Return (TSR)Alpine Rewards LLC
Amicus Therapeutics, Inc.not disclosedOption 33 · RSU 33 · PRSU 33Yes — TSR GoalPay Governance
Apellis Pharmaceuticals, Inc.90.74%RSU 50 · PSU 50not disclosedPay Governance
BioCryst Pharmaceuticals, Inc.not disclosednot disclosednot disclosedAon
CRISPR Therapeutics AGnot disclosednot disclosednot disclosedAlpine Rewards, LLC
Deciphera Pharmaceuticals, Inc.110%Option 50 · PSU 50 · RSU 25NoPearl Meyer & Partners, LLC
Exelixis, Inc.105%PSU 50 · RSU 50Yes — 2025 Relative TSR GoalAon
Halozyme Therapeutics, Inc.127.5%PSU 50 · RSU 35 · Option 15NoF.W. Cook & Co., Inc.
Ionis Pharmaceuticals, Inc.not disclosedPRSU 40 · Option 30 · RSU 30Yes — Relative TSRAon
Mirati Therapeutics, Inc.not disclosedOption 50 · RSU 50not disclosedAon Human Capital Solutions and Alpine Rewards
Neurocrine Biosciences, Inc.105%Options 50 · PSU 30 · RSU 20NoFrederic W. Cook & Co., Inc.
PTC Therapeuticnot disclosedOption 50 · RSU 50Yes — TSR relative to Nasdaq Biotechnology IndexFrederic W. Cook & Co., Inc.
Sarepta Therapeutics, Inc.100%PSU 50 · Option 25 · RSU 25NoFW Cook
Ultragenyx Pharmaceutical Inc.44%PSU 60 · RSU 20 · Options 20Yes — Relative TSRAon's Human Capital Solutions Practice
United Therapeutics, Inc.221%PSO 50 · PSU 50NoAon

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Blueprint Medicines in fiscal 2024?
As disclosed, Kathryn Haviland (President and Chief Executive Officer) was the highest-paid executive at Blueprint Medicines in fiscal 2024, with total compensation of $13,477,004.
How does Blueprint Medicines's chief executive pay compare to its disclosed peer group?
As disclosed, Kathryn Haviland's total compensation ranked at the 76th percentile of Blueprint Medicines's disclosed peer group.
What is Blueprint Medicines's CEO-to-median employee pay ratio?
As disclosed, Blueprint Medicines's CEO-to-median employee pay ratio was 35:1.
How did shareholders vote on Blueprint Medicines's executive compensation?
As disclosed, 95.93% of shareholders supported Blueprint Medicines's executive compensation in the latest say-on-pay vote.
How much does Blueprint Medicines spend in total on board compensation for fiscal 2024?
As disclosed, Blueprint Medicines reported total board compensation of $2,804,894 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Kathryn HavilandDEF 14A2025-04-240001558370-25-005415Section “2024 Summary Compensation Table” · page 52. As printed: 13,477,004. Filing ↗machine: span 1101152–1101162
2Section 01, Christina RossiDEF 14A2025-04-240001558370-25-005415Section “2024 Summary Compensation Table” · page 52. As printed: 6,542,019. Filing ↗machine: span 1130903–1130912
3Section 01, Fouad NamouniDEF 14A2025-04-240001558370-25-005415Section “2024 Summary Compensation Table” · page 52. As printed: 5,497,313. Filing ↗machine: span 1145726–1145735
4Section 01, Percy CarterDEF 14A2025-04-240001558370-25-005415Section “2024 Summary Compensation Table” · page 52. As printed: 5,132,463. Filing ↗machine: span 1160439–1160448
5Section 01, Michael LandsittelDEF 14A2025-04-240001558370-25-005415Section “2024 Summary Compensation Table” · page 52. As printed: 4,191,251. Filing ↗machine: span 1116074–1116083
6Section 03, Michael Landsittel RSUDEF 14A2025-04-240001558370-25-005415Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r17 · c15 · span 1269673–1269682
7Section 03, Kathryn Haviland PSUDEF 14A2025-04-240001558370-25-005415Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r11 · c15 · span 1237576–1237585
8Section 03, Michael Landsittel PSUDEF 14A2025-04-240001558370-25-005415Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r16 · c15 · span 1264378–1264385
9Section 03, Fouad Namouni PSUDEF 14A2025-04-240001558370-25-005415Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r27 · c15 · span 1323347–1323356
10Section 03, Percy Carter PSUDEF 14A2025-04-240001558370-25-005415Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r32 · c15 · span 1350207–1350214
11Section 03, Christina Rossi RSUDEF 14A2025-04-240001558370-25-005415Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r24 · c15 · span 1307084–1307093
12Section 03, Christina Rossi PSUDEF 14A2025-04-240001558370-25-005415Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r21 · c15 · span 1291194–1291203
13Section 03, Fouad Namouni OPTIONDEF 14A2025-04-240001558370-25-005415Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t150 · r14 · c8 · span 1143581–1143590
14Section 03, Percy Carter OPTIONDEF 14A2025-04-240001558370-25-005415Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t150 · r17 · c8 · span 1158294–1158303
15Section 03, Percy Carter RSUDEF 14A2025-04-240001558370-25-005415Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r35 · c15 · span 1366005–1366012
16Section 03, Kathryn Haviland RSUDEF 14A2025-04-240001558370-25-005415Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r12 · c15 · span 1242873–1242882
17Section 03, Christina Rossi RSUDEF 14A2025-04-240001558370-25-005415Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r22 · c15 · span 1296491–1296500
18Section 03, Kathryn Haviland OPTIONDEF 14A2025-04-240001558370-25-005415Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t150 · r5 · c8 · span 1099007–1099016
19Section 03, Percy Carter RSUDEF 14A2025-04-240001558370-25-005415Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r33 · c15 · span 1355502–1355511
20Section 03, Michael Landsittel OPTIONDEF 14A2025-04-240001558370-25-005415Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t150 · r8 · c8 · span 1113929–1113938
21Section 03, Fouad Namouni RSUDEF 14A2025-04-240001558370-25-005415Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r28 · c15 · span 1328644–1328653
22Section 03, Christina Rossi OPTIONDEF 14A2025-04-240001558370-25-005415Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t150 · r11 · c8 · span 1128758–1128767
23Section 07, pay ratioDEF 14A2025-04-240001558370-25-005415Section “CEO Pay Ratio”. As printed: 35 : 1. Filing ↗
24Section 08, Lynn SeelyDEF 14A2025-04-240001558370-25-005415Section “Director Compensation”. As printed: 606,190. Filing ↗machine: span 684459–684658
25Section 08, Mark GoldbergDEF 14A2025-04-240001558370-25-005415Section “Director Compensation”. As printed: 586,690. Filing ↗machine: span 677131–677330
26Section 08, Jeffrey W. AlbersDEF 14A2025-04-240001558370-25-005415Section “Director Compensation”. As printed: 586,190. Filing ↗machine: span 659070–659269
27Section 08, Daniella BeckmanDEF 14A2025-04-240001558370-25-005415Section “Director Compensation”. As printed: 574,690. Filing ↗machine: span 662662–662861
28Section 08, Lonnel CoatsDEF 14A2025-04-240001558370-25-005415Section “Director Compensation”. As printed: 572,590. Filing ↗machine: span 669839–670038
29Section 08, Nicholas LydonDEF 14A2025-04-240001558370-25-005415Section “Director Compensation”. As printed: 569,690. Filing ↗machine: span 680830–681029
30Section 08, Habib DableDEF 14A2025-04-240001558370-25-005415Section “Director Compensation”. As printed: 564,990. Filing ↗machine: span 673434–673633
31Section 08, John TsaiDEF 14A2025-04-240001558370-25-005415Section “Director Compensation”. As printed: 549,690. Filing ↗machine: span 688086–688285
32Section 08, Alexis BorisyDEF 14A2025-04-240001558370-25-005415Section “Director Compensation”. As printed: 549,690. Filing ↗machine: span 666251–666450
33Section 08, Kathryn HavilandDEF 14A2025-04-240001558370-25-005415Section “Director Compensation”. As printed: 0. Filing ↗
34Section 02, Christina Rossi 2025-05-05Form 42025-05-070001415889-25-012250Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Ariel Hurley 2025-05-05Form 42025-05-070001415889-25-012248Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Ariel Hurley 2025-05-05Form 42025-05-070001415889-25-012248Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Ariel Hurley 2025-05-05Form 42025-05-070001415889-25-012248Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Ariel Hurley 2025-05-05Form 42025-05-070001415889-25-012248Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Christina Rossi 2025-05-05Form 42025-05-070001415889-25-012250Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Christina Rossi 2025-05-05Form 42025-05-070001415889-25-012250Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Christina Rossi 2025-05-05Form 42025-05-070001415889-25-012250Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Christina Rossi 2025-05-19Form 42025-05-210001415889-25-013941Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Christina Rossi 2025-05-19Form 42025-05-210001415889-25-013941Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Christina Rossi 2025-05-19Form 42025-05-210001415889-25-013941Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Jeffrey W. Albers 2025-05-27Form 42025-05-290001415889-25-014862Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Jeffrey W. Albers 2025-05-27Form 42025-05-290001415889-25-014862Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Jeffrey W. Albers 2025-05-27Form 42025-05-290001415889-25-014862Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Jeffrey W. Albers 2025-05-27Form 42025-05-290001415889-25-014862Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Percy Carter 2025-06-03Form 42025-06-050001415889-25-015767Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Percy Carter 2025-06-03Form 42025-06-050001415889-25-015767Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Alexis Borisy 2025-06-18Form 42025-06-240001415889-25-018075Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Mark Goldberg 2025-06-18Form 42025-06-240001415889-25-018084Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Lonnel Coats 2025-06-18Form 42025-06-240001415889-25-018069Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, John Tsai 2025-06-18Form 42025-06-240001415889-25-018065Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Daniella Beckman 2025-06-18Form 42025-06-240001415889-25-018078Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Habib Dable 2025-06-18Form 42025-06-240001415889-25-018073Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Jeffrey W. Albers 2025-06-18Form 42025-06-240001415889-25-018086Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Lynn Seely 2025-06-18Form 42025-06-240001415889-25-018082Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Christina Rossi 2025-07-03Form 42025-07-080001415889-25-019507Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Percy Carter 2025-07-03Form 42025-07-080001415889-25-019506Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Michael Landsittel 2025-07-17Form 42025-07-210001104659-25-069396Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Michael Landsittel 2025-07-17Form 42025-07-210001104659-25-069396Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Fouad Namouni 2025-07-17Form 42025-07-210001104659-25-069383Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Mark Goldberg 2025-07-17Form 42025-07-210001104659-25-069384Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Mark Goldberg 2025-07-17Form 42025-07-210001104659-25-069384Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Mark Goldberg 2025-07-17Form 42025-07-210001104659-25-069384Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Mark Goldberg 2025-07-17Form 42025-07-210001104659-25-069384Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Mark Goldberg 2025-07-17Form 42025-07-210001104659-25-069384Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Alexis Borisy 2025-07-17Form 42025-07-210001104659-25-069385Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Christina Rossi 2025-07-17Form 42025-07-210001104659-25-069387Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Christina Rossi 2025-07-17Form 42025-07-210001104659-25-069387Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Lynn Seely 2025-07-17Form 42025-07-210001104659-25-069390Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Lynn Seely 2025-07-17Form 42025-07-210001104659-25-069390Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Lynn Seely 2025-07-17Form 42025-07-210001104659-25-069390Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Lynn Seely 2025-07-17Form 42025-07-210001104659-25-069390Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Lynn Seely 2025-07-17Form 42025-07-210001104659-25-069390Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Tracey L. McCain 2025-07-17Form 42025-07-210001104659-25-069381Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Jeffrey W. Albers 2025-07-17Form 42025-07-210001104659-25-069377Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Jeffrey W. Albers 2025-07-17Form 42025-07-210001104659-25-069377Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Debra Durso-Bumpus 2025-07-17Form 42025-07-210001104659-25-069379Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Jeffrey W. Albers 2025-07-17Form 42025-07-210001104659-25-069377Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Jeffrey W. Albers 2025-07-17Form 42025-07-210001104659-25-069377Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Daniella Beckman 2025-07-17Form 42025-07-210001104659-25-069382Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Debra Durso-Bumpus 2025-07-17Form 42025-07-210001104659-25-069379Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Daniella Beckman 2025-07-17Form 42025-07-210001104659-25-069382Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Kathryn Haviland 2025-07-17Form 42025-07-210001104659-25-069386Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Mark Goldberg 2025-07-17Form 42025-07-210001104659-25-069384Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Kathryn Haviland 2025-07-17Form 42025-07-210001104659-25-069386Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Christina Rossi 2025-07-17Form 42025-07-210001104659-25-069387Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Percy Carter 2025-07-17Form 42025-07-210001104659-25-069388Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Lynn Seely 2025-07-17Form 42025-07-210001104659-25-069390Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, L. Becker Hewes 2025-07-17Form 42025-07-210001104659-25-069391Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Lonnel Coats 2025-07-17Form 42025-07-210001104659-25-069392Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Ariel Hurley 2025-07-17Form 42025-07-210001104659-25-069394Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Habib Dable 2025-07-17Form 42025-07-210001104659-25-069395Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Michael Landsittel 2025-07-17Form 42025-07-210001104659-25-069396Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Michael Landsittel 2025-07-17Form 42025-07-210001104659-25-069396Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Kathryn Haviland 2025-07-17Form 42025-07-210001104659-25-069386Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Kathryn Haviland 2025-07-17Form 42025-07-210001104659-25-069386Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Kathryn Haviland 2025-07-17Form 42025-07-210001104659-25-069386Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Kathryn Haviland 2025-07-17Form 42025-07-210001104659-25-069386Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Percy Carter 2025-07-17Form 42025-07-210001104659-25-069388Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Percy Carter 2025-07-17Form 42025-07-210001104659-25-069388Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Lynn Seely 2025-07-17Form 42025-07-210001104659-25-069390Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, L. Becker Hewes 2025-07-17Form 42025-07-210001104659-25-069391Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, L. Becker Hewes 2025-07-17Form 42025-07-210001104659-25-069391Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, L. Becker Hewes 2025-07-17Form 42025-07-210001104659-25-069391Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Lonnel Coats 2025-07-17Form 42025-07-210001104659-25-069392Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Lonnel Coats 2025-07-17Form 42025-07-210001104659-25-069392Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Ariel Hurley 2025-07-17Form 42025-07-210001104659-25-069394Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Ariel Hurley 2025-07-17Form 42025-07-210001104659-25-069394Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Ariel Hurley 2025-07-17Form 42025-07-210001104659-25-069394Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Ariel Hurley 2025-07-17Form 42025-07-210001104659-25-069394Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Ariel Hurley 2025-07-17Form 42025-07-210001104659-25-069394Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Ariel Hurley 2025-07-17Form 42025-07-210001104659-25-069394Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Habib Dable 2025-07-17Form 42025-07-210001104659-25-069395Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Michael Landsittel 2025-07-17Form 42025-07-210001104659-25-069396Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, Michael Landsittel 2025-07-17Form 42025-07-210001104659-25-069396Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Ariel Hurley 2025-07-17Form 42025-07-210001104659-25-069394Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Philina Lee 2025-07-17Form 42025-07-210001104659-25-069378Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Debra Durso-Bumpus 2025-07-17Form 42025-07-210001104659-25-069379Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Debra Durso-Bumpus 2025-07-17Form 42025-07-210001104659-25-069379Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Debra Durso-Bumpus 2025-07-17Form 42025-07-210001104659-25-069379Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Debra Durso-Bumpus 2025-07-17Form 42025-07-210001104659-25-069379Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Tracey L. McCain 2025-07-17Form 42025-07-210001104659-25-069381Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, Tracey L. McCain 2025-07-17Form 42025-07-210001104659-25-069381Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, Tracey L. McCain 2025-07-17Form 42025-07-210001104659-25-069381Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Tracey L. McCain 2025-07-17Form 42025-07-210001104659-25-069381Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, Tracey L. McCain 2025-07-17Form 42025-07-210001104659-25-069381Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, Tracey L. McCain 2025-07-17Form 42025-07-210001104659-25-069381Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Daniella Beckman 2025-07-17Form 42025-07-210001104659-25-069382Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Mark Goldberg 2025-07-17Form 42025-07-210001104659-25-069384Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, L. Becker Hewes 2025-07-17Form 42025-07-210001104659-25-069391Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, Michael Landsittel 2025-07-17Form 42025-07-210001104659-25-069396Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, L. Becker Hewes 2025-07-17Form 42025-07-210001104659-25-069391Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, Ariel Hurley 2025-07-17Form 42025-07-210001104659-25-069394Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Ariel Hurley 2025-07-17Form 42025-07-210001104659-25-069394Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, Ariel Hurley 2025-07-17Form 42025-07-210001104659-25-069394Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, Habib Dable 2025-07-17Form 42025-07-210001104659-25-069395Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Habib Dable 2025-07-17Form 42025-07-210001104659-25-069395Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, Michael Landsittel 2025-07-17Form 42025-07-210001104659-25-069396Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, Fouad Namouni 2025-07-17Form 42025-07-210001104659-25-069383Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, Fouad Namouni 2025-07-17Form 42025-07-210001104659-25-069383Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, Mark Goldberg 2025-07-17Form 42025-07-210001104659-25-069384Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, Mark Goldberg 2025-07-17Form 42025-07-210001104659-25-069384Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, Mark Goldberg 2025-07-17Form 42025-07-210001104659-25-069384Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, Alexis Borisy 2025-07-17Form 42025-07-210001104659-25-069385Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, Alexis Borisy 2025-07-17Form 42025-07-210001104659-25-069385Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, Alexis Borisy 2025-07-17Form 42025-07-210001104659-25-069385Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, Alexis Borisy 2025-07-17Form 42025-07-210001104659-25-069385Insider equity transaction reported since the proxy statement. Filing ↗
151Section 02, Alexis Borisy 2025-07-17Form 42025-07-210001104659-25-069385Insider equity transaction reported since the proxy statement. Filing ↗
152Section 02, Alexis Borisy 2025-07-17Form 42025-07-210001104659-25-069385Insider equity transaction reported since the proxy statement. Filing ↗
153Section 02, Kathryn Haviland 2025-07-17Form 42025-07-210001104659-25-069386Insider equity transaction reported since the proxy statement. Filing ↗
154Section 02, Kathryn Haviland 2025-07-17Form 42025-07-210001104659-25-069386Insider equity transaction reported since the proxy statement. Filing ↗
155Section 02, Kathryn Haviland 2025-07-17Form 42025-07-210001104659-25-069386Insider equity transaction reported since the proxy statement. Filing ↗
156Section 02, Kathryn Haviland 2025-07-17Form 42025-07-210001104659-25-069386Insider equity transaction reported since the proxy statement. Filing ↗
157Section 02, Kathryn Haviland 2025-07-17Form 42025-07-210001104659-25-069386Insider equity transaction reported since the proxy statement. Filing ↗
158Section 02, Kathryn Haviland 2025-07-17Form 42025-07-210001104659-25-069386Insider equity transaction reported since the proxy statement. Filing ↗
159Section 02, Christina Rossi 2025-07-17Form 42025-07-210001104659-25-069387Insider equity transaction reported since the proxy statement. Filing ↗
160Section 02, Christina Rossi 2025-07-17Form 42025-07-210001104659-25-069387Insider equity transaction reported since the proxy statement. Filing ↗
161Section 02, Christina Rossi 2025-07-17Form 42025-07-210001104659-25-069387Insider equity transaction reported since the proxy statement. Filing ↗
162Section 02, Percy Carter 2025-07-17Form 42025-07-210001104659-25-069388Insider equity transaction reported since the proxy statement. Filing ↗
163Section 02, Percy Carter 2025-07-17Form 42025-07-210001104659-25-069388Insider equity transaction reported since the proxy statement. Filing ↗
164Section 02, Percy Carter 2025-07-17Form 42025-07-210001104659-25-069388Insider equity transaction reported since the proxy statement. Filing ↗
165Section 02, Lynn Seely 2025-07-17Form 42025-07-210001104659-25-069390Insider equity transaction reported since the proxy statement. Filing ↗
166Section 02, Lynn Seely 2025-07-17Form 42025-07-210001104659-25-069390Insider equity transaction reported since the proxy statement. Filing ↗
167Section 02, Lynn Seely 2025-07-17Form 42025-07-210001104659-25-069390Insider equity transaction reported since the proxy statement. Filing ↗
168Section 02, Lynn Seely 2025-07-17Form 42025-07-210001104659-25-069390Insider equity transaction reported since the proxy statement. Filing ↗
169Section 02, L. Becker Hewes 2025-07-17Form 42025-07-210001104659-25-069391Insider equity transaction reported since the proxy statement. Filing ↗
170Section 02, L. Becker Hewes 2025-07-17Form 42025-07-210001104659-25-069391Insider equity transaction reported since the proxy statement. Filing ↗
171Section 02, L. Becker Hewes 2025-07-17Form 42025-07-210001104659-25-069391Insider equity transaction reported since the proxy statement. Filing ↗
172Section 02, Lonnel Coats 2025-07-17Form 42025-07-210001104659-25-069392Insider equity transaction reported since the proxy statement. Filing ↗
173Section 02, Jeffrey W. Albers 2025-07-17Form 42025-07-210001104659-25-069377Insider equity transaction reported since the proxy statement. Filing ↗
174Section 02, Jeffrey W. Albers 2025-07-17Form 42025-07-210001104659-25-069377Insider equity transaction reported since the proxy statement. Filing ↗
175Section 02, Jeffrey W. Albers 2025-07-17Form 42025-07-210001104659-25-069377Insider equity transaction reported since the proxy statement. Filing ↗
176Section 02, Philina Lee 2025-07-17Form 42025-07-210001104659-25-069378Insider equity transaction reported since the proxy statement. Filing ↗
177Section 02, Philina Lee 2025-07-17Form 42025-07-210001104659-25-069378Insider equity transaction reported since the proxy statement. Filing ↗
178Section 02, Philina Lee 2025-07-17Form 42025-07-210001104659-25-069378Insider equity transaction reported since the proxy statement. Filing ↗
179Section 02, Philina Lee 2025-07-17Form 42025-07-210001104659-25-069378Insider equity transaction reported since the proxy statement. Filing ↗
180Section 02, Debra Durso-Bumpus 2025-07-17Form 42025-07-210001104659-25-069379Insider equity transaction reported since the proxy statement. Filing ↗
181Section 02, Debra Durso-Bumpus 2025-07-17Form 42025-07-210001104659-25-069379Insider equity transaction reported since the proxy statement. Filing ↗
182Section 02, Debra Durso-Bumpus 2025-07-17Form 42025-07-210001104659-25-069379Insider equity transaction reported since the proxy statement. Filing ↗
183Section 02, Debra Durso-Bumpus 2025-07-17Form 42025-07-210001104659-25-069379Insider equity transaction reported since the proxy statement. Filing ↗
184Section 02, Debra Durso-Bumpus 2025-07-17Form 42025-07-210001104659-25-069379Insider equity transaction reported since the proxy statement. Filing ↗
185Section 02, Tracey L. McCain 2025-07-17Form 42025-07-210001104659-25-069381Insider equity transaction reported since the proxy statement. Filing ↗
186Section 02, Tracey L. McCain 2025-07-17Form 42025-07-210001104659-25-069381Insider equity transaction reported since the proxy statement. Filing ↗
187Section 02, Tracey L. McCain 2025-07-17Form 42025-07-210001104659-25-069381Insider equity transaction reported since the proxy statement. Filing ↗
188Section 02, Tracey L. McCain 2025-07-17Form 42025-07-210001104659-25-069381Insider equity transaction reported since the proxy statement. Filing ↗
189Section 02, Tracey L. McCain 2025-07-17Form 42025-07-210001104659-25-069381Insider equity transaction reported since the proxy statement. Filing ↗
190Section 02, Fouad Namouni 2025-07-17Form 42025-07-210001104659-25-069383Insider equity transaction reported since the proxy statement. Filing ↗
191Section 02, Christina Rossi 2025-07-17Form 42025-07-210001104659-25-069387Insider equity transaction reported since the proxy statement. Filing ↗
192Section 02, Christina Rossi 2025-07-17Form 42025-07-210001104659-25-069387Insider equity transaction reported since the proxy statement. Filing ↗
193Section 02, Christina Rossi 2025-07-17Form 42025-07-210001104659-25-069387Insider equity transaction reported since the proxy statement. Filing ↗
194Section 02, Christina Rossi 2025-07-17Form 42025-07-210001104659-25-069387Insider equity transaction reported since the proxy statement. Filing ↗
195Section 02, Lonnel Coats 2025-07-17Form 42025-07-210001104659-25-069392Insider equity transaction reported since the proxy statement. Filing ↗
196Section 02, Lonnel Coats 2025-07-17Form 42025-07-210001104659-25-069392Insider equity transaction reported since the proxy statement. Filing ↗
197Section 02, Lonnel Coats 2025-07-17Form 42025-07-210001104659-25-069392Insider equity transaction reported since the proxy statement. Filing ↗
198Section 02, Lonnel Coats 2025-07-17Form 42025-07-210001104659-25-069392Insider equity transaction reported since the proxy statement. Filing ↗
199Section 02, Lonnel Coats 2025-07-17Form 42025-07-210001104659-25-069392Insider equity transaction reported since the proxy statement. Filing ↗
200Section 02, Percy Carter 2025-07-17Form 42025-07-210001104659-25-069388Insider equity transaction reported since the proxy statement. Filing ↗
201Section 02, Percy Carter 2025-07-17Form 42025-07-210001104659-25-069388Insider equity transaction reported since the proxy statement. Filing ↗
202Section 02, John Tsai 2025-07-17Form 42025-07-210001104659-25-069393Insider equity transaction reported since the proxy statement. Filing ↗
203Section 02, John Tsai 2025-07-17Form 42025-07-210001104659-25-069393Insider equity transaction reported since the proxy statement. Filing ↗
204Section 02, John Tsai 2025-07-17Form 42025-07-210001104659-25-069393Insider equity transaction reported since the proxy statement. Filing ↗
205Section 02, John Tsai 2025-07-17Form 42025-07-210001104659-25-069393Insider equity transaction reported since the proxy statement. Filing ↗
206Section 02, Daniella Beckman 2025-07-17Form 42025-07-210001104659-25-069382Insider equity transaction reported since the proxy statement. Filing ↗
207Section 02, Daniella Beckman 2025-07-17Form 42025-07-210001104659-25-069382Insider equity transaction reported since the proxy statement. Filing ↗
208Section 02, Daniella Beckman 2025-07-17Form 42025-07-210001104659-25-069382Insider equity transaction reported since the proxy statement. Filing ↗
209Section 02, Habib Dable 2025-07-17Form 42025-07-210001104659-25-069395Insider equity transaction reported since the proxy statement. Filing ↗
210Section 02, Fouad Namouni 2025-07-17Form 42025-07-210001104659-25-069383Insider equity transaction reported since the proxy statement. Filing ↗
211Section 02, Fouad Namouni 2025-07-17Form 42025-07-210001104659-25-069383Insider equity transaction reported since the proxy statement. Filing ↗
212Section 02, Fouad Namouni 2025-07-17Form 42025-07-210001104659-25-069383Insider equity transaction reported since the proxy statement. Filing ↗
213Section 02, Fouad Namouni 2025-07-17Form 42025-07-210001104659-25-069383Insider equity transaction reported since the proxy statement. Filing ↗
214Section 02, Fouad Namouni 2025-07-17Form 42025-07-210001104659-25-069383Insider equity transaction reported since the proxy statement. Filing ↗
215Section 02, Alexis Borisy 2025-07-17Form 42025-07-210001104659-25-069385Insider equity transaction reported since the proxy statement. Filing ↗
216Section 02, Alexis Borisy 2025-07-17Form 42025-07-210001104659-25-069385Insider equity transaction reported since the proxy statement. Filing ↗
217Section 02, Michael Landsittel 2025-07-17Form 42025-07-210001104659-25-069396Insider equity transaction reported since the proxy statement. Filing ↗
218Section 02, Michael Landsittel 2025-07-17Form 42025-07-210001104659-25-069396Insider equity transaction reported since the proxy statement. Filing ↗
219Section 02, Michael Landsittel 2025-07-17Form 42025-07-210001104659-25-069396Insider equity transaction reported since the proxy statement. Filing ↗
220Section 02, Jeffrey W. Albers 2025-07-17Form 42025-07-210001104659-25-069377Insider equity transaction reported since the proxy statement. Filing ↗
221Section 02, Jeffrey W. Albers 2025-07-17Form 42025-07-210001104659-25-069377Insider equity transaction reported since the proxy statement. Filing ↗
222Section 02, Jeffrey W. Albers 2025-07-17Form 42025-07-210001104659-25-069377Insider equity transaction reported since the proxy statement. Filing ↗
223Section 02, John Tsai 2025-07-17Form 42025-07-210001104659-25-069393Insider equity transaction reported since the proxy statement. Filing ↗
224Section 02, Michael Landsittel 2025-07-17Form 42025-07-210001104659-25-069396Insider equity transaction reported since the proxy statement. Filing ↗
225Section 02, Lonnel Coats 2025-07-17Form 42025-07-210001104659-25-069392Insider equity transaction reported since the proxy statement. Filing ↗
226Section 02, Lynn Seely 2025-07-17Form 42025-07-210001104659-25-069390Insider equity transaction reported since the proxy statement. Filing ↗
227Section 02, Philina Lee 2025-07-17Form 42025-07-210001104659-25-069378Insider equity transaction reported since the proxy statement. Filing ↗
228Section 02, Philina Lee 2025-07-17Form 42025-07-210001104659-25-069378Insider equity transaction reported since the proxy statement. Filing ↗
229Section 02, Ariel Hurley 2025-07-17Form 42025-07-210001104659-25-069394Insider equity transaction reported since the proxy statement. Filing ↗
230Section 02, Philina Lee 2025-07-17Form 42025-07-210001104659-25-069378Insider equity transaction reported since the proxy statement. Filing ↗
231Section 02, Kathryn Haviland 2025-07-17Form 42025-07-210001104659-25-069386Insider equity transaction reported since the proxy statement. Filing ↗
232Section 02, Christina Rossi 2025-07-17Form 42025-07-210001104659-25-069387Insider equity transaction reported since the proxy statement. Filing ↗
233Section 02, Tracey L. McCain 2025-07-17Form 42025-07-210001104659-25-069381Insider equity transaction reported since the proxy statement. Filing ↗
234Section 06, 2025 voteForm 8-K2025-06-200001558370-25-008742Item 5.07 · say-on-pay result. As reported: 95.93% (votes for as printed: 57,714,069). Filing ↗
235Section 06, 2024 voteForm 8-K2024-06-140001104659-24-071734Item 5.07 · say-on-pay result. As reported: 97.69% (votes for as printed: 56,844,879). Filing ↗
236Section 06, 2023 voteForm 8-K2023-06-270001104659-23-075235Item 5.07 · say-on-pay result. As reported: 98.17% (votes for as printed: 54,299,704). Filing ↗
237Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
238Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
239Section 09b board cost (computed)Computed——Cash 628,200 + equity 2,141,694 + all other 35,000 = 2,804,894, summed across the director compensation table rows.machine: formula: Σ = 2,804,894
240Exelixis, Inc., Section 10b CEO totalDEF 14A2026-04-150000939767-26-000046CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526
241PTC Therapeutic, Section 10b CEO totalDEF 14A2026-04-200001104659-26-045528CEO total compensation as printed in PTC Therapeutic's own proxy. As printed: 23,266,326. Filing ↗
242Halozyme Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-03-230001159036-26-000041CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292
243United Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-290001082554-26-000009CEO total compensation as printed in United Therapeutics, Inc.'s own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736
244Blueprint Medicines (subject), Section 10b CEO totalDEF 14A2025-04-240001558370-25-005415CEO total compensation as printed in Blueprint Medicines's own proxy. As printed: 13,477,004. Filing ↗machine: span 1101152–1101162
245Neurocrine Biosciences, Inc., Section 10b CEO totalDEF 14A2026-04-150000914475-26-000015CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957
246Ionis Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-230001140361-26-016388CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗
247BioCryst Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-230001628280-26-026822CEO total compensation as printed in BioCryst Pharmaceuticals, Inc.'s own proxy. As printed: 12,951,082. Filing ↗machine: span 512256–512266
248Mirati Therapeutics, Inc., Section 10b CEO totalDEF 14A2023-04-060001628280-23-011004CEO total compensation as printed in Mirati Therapeutics, Inc.'s own proxy. As printed: 11,937,371. Filing ↗machine: r2 · c45 · span 540567–540577
249Ultragenyx Pharmaceutical Inc., Section 10b CEO totalDEF 14A2026-03-270001308179-26-000174CEO total compensation as printed in Ultragenyx Pharmaceutical Inc.'s own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007
250Apellis Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2025-04-230000950170-25-056966CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565
251Amicus Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-240001140361-25-015479CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136
252ACADIA Pharmaceuticals Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-174163CEO total compensation as printed in ACADIA Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. Filing ↗
253Alkermes, Inc., Section 10b CEO totalDEF 14A2026-04-060001193125-26-143977CEO total compensation as printed in Alkermes, Inc.'s own proxy. As printed: 7,915,081. Filing ↗machine: r3 · c33 · span 2508258–2508267
254Sarepta Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177247CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. Filing ↗machine: span 1454395–1454404
255CRISPR Therapeutics AG, Section 10b CEO totalDEF 14A2026-04-210001193125-26-165158CEO total compensation as printed in CRISPR Therapeutics AG's own proxy. As printed: 7,678,477. Filing ↗machine: r2 · c25 · span 821649–821658
256Deciphera Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2024-04-250001654151-24-000012CEO total compensation as printed in Deciphera Pharmaceuticals, Inc.'s own proxy. As printed: 6,010,712. Filing ↗machine: span 605886–605895
257Agios Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177086CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. Filing ↗machine: r2 · c31 · span 613185–613194
258Section 10a, Apellis Pharmaceuticals, Inc. reciprocityDEF 14A—0000950170-25-056966Apellis Pharmaceuticals, Inc. names Blueprint Medicines in its own disclosed peer group (read from its most recent proxy). Filing ↗
259Section 10a, Deciphera Pharmaceuticals, Inc. reciprocityDEF 14A—0001654151-24-000012Deciphera Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Blueprint Medicines. Filing ↗
260Section 10a, Mirati Therapeutics, Inc. reciprocityDEF 14A—0001628280-23-011004Mirati Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Blueprint Medicines. Filing ↗
261Section 10a, United Therapeutics, Inc. reciprocityDEF 14A—0001082554-26-000009United Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Blueprint Medicines. Filing ↗
262Section 10a, PTC Therapeutic reciprocityDEF 14A—0001104659-26-045528PTC Therapeutic names Blueprint Medicines in its own disclosed peer group (read from its most recent proxy). Filing ↗
263Section 10a, Sarepta Therapeutics, Inc. reciprocityDEF 14A—0001193125-26-177247Sarepta Therapeutics, Inc. names Blueprint Medicines in its own disclosed peer group (read from its most recent proxy). Filing ↗
264Section 10a, Ultragenyx Pharmaceutical Inc. reciprocityDEF 14A—0001308179-26-000174Ultragenyx Pharmaceutical Inc. names Blueprint Medicines in its own disclosed peer group (read from its most recent proxy). Filing ↗
265Section 10a, Halozyme Therapeutics, Inc. reciprocityDEF 14A—0001159036-26-000041Halozyme Therapeutics, Inc. names Blueprint Medicines in its own disclosed peer group (read from its most recent proxy). Filing ↗
266Section 10a, ACADIA Pharmaceuticals Inc. reciprocityDEF 14A—0001193125-26-174163ACADIA Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Blueprint Medicines. Filing ↗
267Section 10a, BioCryst Pharmaceuticals, Inc. reciprocityDEF 14A—0001628280-26-026822BioCryst Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Blueprint Medicines. Filing ↗
268Section 10a, Neurocrine Biosciences, Inc. reciprocityDEF 14A—0000914475-26-000015Neurocrine Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Blueprint Medicines. Filing ↗
269Section 10a, Amicus Therapeutics, Inc. reciprocityDEF 14A—0001140361-25-015479Amicus Therapeutics, Inc. names Blueprint Medicines in its own disclosed peer group (read from its most recent proxy). Filing ↗
270Section 10a, Agios Pharmaceuticals, Inc. reciprocityDEF 14A—0001193125-26-177086Agios Pharmaceuticals, Inc. names Blueprint Medicines in its own disclosed peer group (read from its most recent proxy). Filing ↗
271Section 10a, Ionis Pharmaceuticals, Inc. reciprocityDEF 14A—0001140361-26-016388Ionis Pharmaceuticals, Inc. names Blueprint Medicines in its own disclosed peer group (read from its most recent proxy). Filing ↗
272Section 10a, CRISPR Therapeutics AG reciprocityDEF 14A—0001193125-26-165158CRISPR Therapeutics AG names Blueprint Medicines in its own disclosed peer group (read from its most recent proxy). Filing ↗
273Section 10a, Exelixis, Inc. reciprocityDEF 14A—0000939767-26-000046Exelixis, Inc.'s most recent proxy was read; its disclosed peer group does not include Blueprint Medicines. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.